• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

    11/18/24 7:00:00 AM ET
    $EVO
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EVO alert in real time by email

    Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies

    Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond

    All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close

    SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.

    The presentation highlights include:

    The acquisition of Evotec would be a logical extension and diversification of Halozyme's business, and is aligned with Halozyme's M&A criteria:

    • De-risked business: Evotec has a large, diverse revenue base with expected future revenue and margin expansion opportunities.
    • Structurally similar business model: Evotec has a proprietary and innovative platform of technologies in drug discovery, development and biologic manufacturing.
    • Strong biopharma partnerships: Evotec partners with more than 500 biopharma companies globally.
    • Potential for durable long-term revenue growth: Evotec has platform opportunities and a pipeline that would be additive to future potential revenue streams.

    The combination would create a unique B2B global innovative pharma services company with complementary and leverageable platforms and cross-selling opportunities:

    • Drug discovery: Evotec's Shared R&D platform is an established and comprehensive continuum of innovative discovery platform tools with a strong track record of success and more than 500 partners and 140+ partnered and unpartnered asset opportunities.
    • Continuous biologics manufacturing: Just – Evotec Biologics is a pioneer in end-to-end continuous manufacturing, a breakthrough biologic manufacturing capability with 10 products in late-stage development and clinical manufacturing and more than 50 products in CMC development/IND enabling.
    • Drug delivery: Halozyme's ENHANZE® drug delivery technology is the leading, commercially-validated solution to facilitate the subcutaneous delivery of large volume injected biologic drugs, currently approved in eight products in more than 100 global markets, with expected near-term approvals, a robust pipeline in development and new deal opportunities.

    The combination would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond.

    • Establishes a diversified pharma services portfolio with approximately $2 billion in annual revenue projected in 2025.
    • Enhances long-term growth profile and maintains 15-20%+ 2023A – 2028E revenue CAGR while extending and accelerating growth into the next decade and beyond.
    • Delivers robust long-term margin profile with a pro forma 45- 50% adjusted EBITDA margin by 2026 and significant cash flow generation over time.

    The all-cash transaction would be supported by an existing lender group with a clear path to less than 2x net leverage within two years post-close.

    • Halozyme has significant cash reserves on-hand and a strong balance sheet with cash projected to be more than $800 million at year-end 2024.The transaction would not be subject to a financing condition.
    • Halozyme is working with financing relationship partners on optimal financing structure and confirms equity will not be used to finance the transaction.
    • Assuming a transaction is consummated, net debt on balance sheet at close would be approximately $3 billion, with a significant portion prepayable, and net leverage for funding at transaction close projected to be less than 4.75x.
    • Net leverage is expected to decrease to less than 2x within two years post-close and quickly reducing meaningfully below that level through debt paydown and adjusted EBITDA growth, with additional multiple levers to further accelerate debt paydown over time.

    For more information about Halozyme, its strategy, financials and capital allocation priorities, please visit https://ir.halozyme.com/overview/default.aspx.

    Advisors

    Centerview Partners is serving as Halozyme's financial advisor and Weil, Gotshal & Manges LLP, as legal advisor.

    About Halozyme

    Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

    Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

    Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

    For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

    Forward-Looking Statements

    In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's and Evotec's expected future financial performance and growth rates, including expectations for future total revenues, gross margin expansion, and adjusted EBITDA margin, as well as the Company's future plans, objectives, expectations and intentions relating to a potential transaction concerning Evotec, such potential transaction's expected impact and contributions to the Company's and the combined group's operations and financial results, the financing and closing of such potential transaction, as well as the expected timing and benefits of such potential  transaction, the Company's and Evotec's future product development and regulatory events and goals, product collaborations, the Company's business intentions and financial statements and anticipated results.  These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "can," "durable," "growth," "innovate," "potential," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including  uncertainties concerning future matters such as market conditions, changes in domestic and foreign business changes in the competitive environment in which the Company and Evotec operate, discussions with Evotec and its board of directors, and financing a potential transaction, inability of the parties to successfully or timely enter into or consummate a transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined group or the expected benefits of a transaction, unexpected levels of the combined group's revenues, expenditures and costs, unexpected results or delays in the growth of the combined group's business, or in the development, regulatory review or commercialization of the combined group's partnered or proprietary products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release.

    Non-GAAP Financial Measures:

    These materials contain certain non-GAAP financial measures and projections. The Company reports Adjusted EBITDA, Adjusted EBITDA Margin and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company does not provide reconciliations for forward-looking adjusted measures to GAAP, including as to the projected benefits of the potential transaction concerning Evotec, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation.

    Halozyme Contacts

    Investors

    Tram Bui

    Halozyme VP, Investor Relations and Corporate Communications

    609-359-3016

    [email protected]

    U.S. Media

    Andrea Calise

    Teneo

    917-826-3804

    [email protected] 

    Christina Coronios

    Teneo

    646-531-2882

    [email protected] 

    German Media

    Felix Schoenauer

    Teneo

    +49 69 867906054

    [email protected] 

    Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-provides-update-on-non-binding-proposal-to-combine-with-evotec-302308095.html

    SOURCE Halozyme Therapeutics, Inc.

    Get the next $EVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVO
    $HALO

    CompanyDatePrice TargetRatingAnalyst
    Evotec SE
    $EVO
    4/24/2025Sell → Hold
    Deutsche Bank
    Halozyme Therapeutics Inc.
    $HALO
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    Evotec SE
    $EVO
    10/7/2024Buy → Hold
    Jefferies
    Halozyme Therapeutics Inc.
    $HALO
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    Evotec SE
    $EVO
    8/8/2024Hold → Sell
    Deutsche Bank
    Evotec SE
    $EVO
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    Evotec SE
    $EVO
    7/11/2024Buy → Hold
    Deutsche Bank
    Halozyme Therapeutics Inc.
    $HALO
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $EVO
    $HALO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Halozyme Therapeutics Inc.

      10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:08:30 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

      5/6/25 4:06:31 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Evotec SE

      6-K - Evotec SE (0001412558) (Filer)

      5/6/25 6:00:17 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

      SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the

      5/5/25 5:15:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EVO
    $HALO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evotec SE upgraded by Deutsche Bank

      Deutsche Bank upgraded Evotec SE from Sell to Hold

      4/24/25 7:18:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Halozyme Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal Weight and set a new price target of $62.00 from $58.00 previously

      10/7/24 8:32:56 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evotec SE downgraded by Jefferies

      Jefferies downgraded Evotec SE from Buy to Hold

      10/7/24 7:52:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    $HALO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

      SC 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      11/12/24 9:36:57 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Evotec SE

      SC 13D - Evotec SE (0001412558) (Subject)

      11/8/24 9:43:55 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Halozyme Therapeutics Inc.

      SC 13G - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

      10/17/24 9:36:19 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EVO
    $HALO
    Financials

    Live finance-specific insights

    See more
    • HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

      Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

      5/6/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report First Quarter 2025 Financial and Operating Results

      SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

      4/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

      Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance  Reiterating 2025 Finan

      2/18/25 4:01:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EVO
    $HALO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:11:14 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:09:44 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)

      4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)

      5/2/25 4:08:05 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EVO
    $HALO
    Leadership Updates

    Live Leadership Updates

    See more
    • Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

      Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm

      9/26/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Evotec SE: Results of the Annual General Meeting 2024

      Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina

      6/10/24 12:15:00 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care